Actively Recruiting

Phase 4
Age: 18Years - 65Years
All Genders
NCT05461820

Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease

Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2023-12-11

240

Participants Needed

1

Research Sites

639 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal were evaluated. At the same time, the changes of immune indexes and inflammatory factors in the regulation process were evaluated. This study is a phase IV clinical study designed and carried out by the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), which is a randomized, open and routine treatment group with parallel control.

CONDITIONS

Official Title

Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Graves hyperthyroidism diagnosed by a doctor
  • Age between 18 and 65 years, any gender
  • Positive thyroid receptor antibody (TRAb) test
  • Voluntary participation with signed informed consent
Not Eligible

You will not qualify if you...

  • Use of glucocorticoids or immunosuppressants for a long time within 3 months before selection
  • Participation in any other drug trials within 3 months before selection
  • Currently involved in clinical research of other drugs
  • History of malignant tumors
  • Poorly controlled high blood pressure (diastolic 60 100 mmHg or systolic 60 160 mmHg)
  • Low white blood cell or neutrophil counts below specified limits
  • Other thyroid diseases such as subacute thyroiditis, thyroid nodules, or high-function adenoma
  • Elevated liver enzymes more than twice the normal limit or positive hepatitis B tests
  • Kidney problems with high serum creatinine
  • Heart failure or coronary heart disease
  • Other autoimmune diseases
  • Known allergy to methimazole or its components
  • Multiple drug allergies or high sensitivity
  • Alcoholism, mental disorders, or unsuitable for drug testing
  • Pregnant or breastfeeding women or possible pregnancy
  • Use of medicines with unknown ingredients or traditional Chinese medicine affecting treatment
  • Other medical conditions or lifestyle factors that may complicate participation or follow-up
  • Compliance outside 80%-120% during the trial
  • Inability to cooperate or complete treatment and follow-up as planned
  • Use of other drugs affecting the trial during the study
  • Allergic or intolerant reactions to the study drug
  • Development of other diseases interfering with treatment observation
  • Pregnancy during the trial
  • Investigator's judgment deeming inappropriate to continue participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

the First Affiliated Hospital of Nanjing Medical University

Nanjing, China

Actively Recruiting

Loading map...

Research Team

X

Xuqin Zheng

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here